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(Treg) cells, but also expressed in activated human helper T cells without acquisition of a regulatory phenotype. This
comment focuses on glycoprotein-A repetitions predominant (GARP or LRRC32) recently identified as specific mar-
ker of activated human Treg cells, which may provide the missing link toward a better molecular definition of the
regulatory phenotype.
Reviewers: Dr Jim Di Danto, Dr Benedita Rocha and Dr Werner Solbach.
Introduction
Proposed role of FOXP3 in self-tolerance
The maintenance of self-tolerance involves central and
peripheral mechanisms, but the process of thymic nega-
tive selection is imperfect. Self-reacting clones that
escape central tolerance are kept in check by a variety
of peripheral tolerance mechanisms, in which the domi-
nant tolerance exerted by CD4
+CD25
+ regulatory T
(Treg) cells plays an important role. The development
and function of Treg cells crucially depends on the fork-
head/winged helix transcription factor FOXP3. This
dependence is compellingly illustrated by the fact that
loss of function of FOXP3 leads to the development of
the fatal autoimmune lymphoproliferative disorder IPEX
(immunodysregulation, polyendocrinopathy, and entero-
pathy, X-linked) syndrome [1,2]. Similarly, loss of func-
tion of FoxP3 in mice, either natural (scurfy)o r
recombinant, results in an analogous immune pathology
due to a lack of Treg cells [3-5]. The dominant role of
FOXP3 is further corroborated by the fact that the gain
of function induced by ectopic expression in conven-
tional CD4
+CD25
- helper T (Th) cells leads to the acqui-
sition of suppressor function and the induction of a
partial regulatory phenotype in mice and humans
[3,6-8].
Despite advances in our understanding of Treg-cell
lineage commitment and function, gained mainly by the
study of FoxP3 knock-out/knock-in mice [4,5,9-11], the
dominant role of FOXP3 in the human system and its
suitability as a bona fide marker of human Treg cells
have been questioned [8,12-14].
Why should Treg cells need more than FOXP3?
The reasoning that more than FOXP3 is necessary for
fully explaining the regulatory phenotype in humans is
supported by several observations. First, T-cell receptor
(TCR) stimulation of CD4
+CD25
-FOXP3
- T cells leads
to the induction of FOXP3 without interfering with the
expression of effector cytokines such as interleukin-2
and interferon-g [15-17]. Second, the expression of
FOXP3 by conventional CD4
+CD25
- Th cells and even
by Th lines and clones does not necessarily indicate the
acquisition of suppressor function [8,12,17-19]. Third,
and more specifically, it has recently been found that
demethylation of a conserved FOXP3 intronic region
may be a better marker for suppressor function than the
differential expression of FOXP3 at the mRNA or pro-
tein level in Treg and Th cell clones [20]. Fourth, ectopic
expression of FOXP3 in human Th cells does not lead
to the establishment of a stable regulatory phenotype
[8,12,21]. Finally, although the enhancement of FOXP3
expression by transforming growth factor-b1( T G F - b1)
in activated human CD4
+CD25
- Th cells generates so-
called induced Treg (iTreg) cells, this phenotype is rapidly
lost [19,21,22]. Altogether, these observations suggest
that more than FOXP3 is necessary for fully explaining
the regulatory phenotype.
A plausible explanation for the qualitative and quanti-
tative differences in the expression of FOXP3 in human
Th and Treg cells, with their mutually exclusive effector
* Correspondence: m.probst-kepper@klinikum-braunschweig.de
1Institute for Microbiology, Immunology and Hygiene, Städtisches Klinikum
Braunschweig gGmbH, Braunschweig, Germany
Probst-Kepper and Buer Biology Direct 2010, 5:8
http://www.biology-direct.com/content/5/1/8
© 2010 Probst-Kepper and Buer; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.and regulatory functions, is the presence of a Treg-speci-
fic higher-order regulatory network [13,14,23]. The pos-
sibility that Treg-specific control mechanisms can
maintain sustained high levels of FOXP3 and can con-
trol the regulatory function has been addressed only
recently with the identification of the glycoprotein-A
repetitions predominant (GARP or LRRC32) receptor
[21,24-28].
Identification and characterization of GARP as a
safeguard of FOXP3
GARP was identified based on the analysis of gene
expression profiling of Treg and Th cells following TCR
stimulation, since TCR stimulation does lead to the
induction of their mutually exclusive functions [21,24].




Treg cells and thus is a Treg-specific activation marker
[21,24-27]. Because the expression of GARP is up-regu-
lated in FOXP3-transduced Th cells, GARP obviously
depends on FOXP3, and this finding suggests a potential
contribution to the regulatory phenotype [21,29].
The function of GARP has been elucidated by ectopic
over-expression in human alloantigen-specific Th cells
and down-regulation of GARP in human antigen-speci-
fic Treg cells [21,29]. Retroviral over-expression of GARP
in Th cells, after some rounds of TCR stimulation, leads
to an efficient and stable reprogramming/transdifferen-
tiation of the established effector toward the regulatory
program. This finding is associated with constitutive
expression of FOXP3, the b-galactoside binding protein
lectin, galactoside-binding, soluble, 3 (LGALS3) [8,30],
and the cysteine-endoprotease legumain (LGMN) [8]
and with an extended Treg-signature with suppression of
effector cytokine production and acquisition of regula-
tory functions similar to those of Treg cells [21,29].
Thus, a FOXP3-regulating gene has been identified in
the human system, and this finding suggests that the
GARP signaling pathway may have direct therapeutic
applications [28,31] similar to those that have been
described for CD83 in the murine system [32].
In contrast, lentiviral down-regulation of GARP in
human alloantigen-specific Treg c e l l sb ys p e c i f i cs m a l l
interfering RNA (siRNA) substantially impairs suppres-
sor function and FOXP3 expression that is associated
with impaired induction of CD83 and CD27, both
known to regulate FOXP3 [21,32,33]. More striking is
the fact that similar changes are induced by the down-
regulation of FOXP3 in Treg cells, a finding that pro-
vides compelling evidence for a GARP-FOXP3 positive
feedback loop in Treg cells. Because this feedback loop
seems to be interrelated witho t h e rF O X P 3 - r e g u l a t i n g
systems such as CD83 and CD27, the existence of a
higher-order regulatory network as discussed recently by
Hori [13], can be speculated (Figure 1a).
Thus, GARP is a specific marker of activated Treg cells
and can explain the qualitative and quantitative differ-
ences in FOXP3 expression and function in Treg cells
and Th cells. Lack of GARP expression further differ-
entiates and explains the transient nature of TGF-b-
induced iTreg cells [19], suggesting that natural and iTreg
cells may represent alternative differentiation stages of
suppressor cells [21,26]. In line with these observations,
a specifically hypomethylated region in intron 1 of
GARP and two differentially methylated regions with
enhancer functions in Treg cells have recently been char-
acterized. These findings have identified an epigenetic
basis for the lineage-specific difference in GARP expres-
sion [34].
GARP brings latent TGF-b into a new game
Members of the TGF-b family are pleiotropic cytokines
with crucial functions in differentiation, morphogenesis,
and immune homeostasis. Their function in immune
homeostasis is evidenced by the fact that dysregulation
of TGF-b functions is associated with autoimmunity
[35]. Like many other cell types, human Treg and Th
cells can secrete latent TGF-b [20,36]. However,
latency-associated peptide (LAP) prevents the activation
of latent TGF-b toward the active mature TGF-b [37].
The selective induction of LAP and the activation of
active TGF-b upon TCR stimulation has been reported
only for human Treg cells and clones [20,37,38]. This
finding further explains the TGF-b specific transcrip-
tional signature and detection of expression of phos-
phorylated SMAD2 in Treg cells of human and murine
origin [20,23,37,39]. Moreover, specific up-regulation of
LAP on activated human Treg cells has been shown to
allow improvements in the purity of Treg cell isolation
procedures by separating activated LAP
+FOXP3
+ Treg
cells from contaminating effector LAP
-FOXP3
+/lo Th
cells [38]. Thus, besides being a marker of activated Treg
cells in complex with LAP, TGF-b1 is an important
modulator of FOXP3 expression [19,21,40], and a poten-
tial mediator of infectious tolerance by its action in con-
verting FoxP3
- murine CD4
+ T cells into functional
FoxP3
+ iTreg cells [41].
The issue of cell-surface binding of LAP/latent TGF-b
on human Treg cells has been addressed only recently
with the identification of GARP as a receptor of this
complex [26,27]. Therefore, two important regulatory
circuits of Treg cells come together: the GARP-FOXP3
feedback loop and the autocrine TGF-b loop (Figure
1b). With that, the potential synergy of many of the Treg
signature components that are essential for the regula-
tory properties that have been ascribed to TCR activa-
t i o n ,i n t e r l e u k i n - 2 ,T G F - b,a n dF O X P 3i t s e l f[ 2 0 , 2 3 ]
could be explained by this particular spatiotemporal
interplay of interrelated signaling systems on Treg cells.
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Page 2 of 6Figure 1 GARP as safeguard of the regulatory phenotype.( A) Qualitative (lineage-specific) and quantitative (dose-effect) differences in
FOXP3 expression in human helper T cells (Th; upper panel) and regulatory T cells (Treg; lower panel) are due to lineage-specific methylation of
the respective loci (indicated by black dots) and thus the expression of the genes FOXP3 and GARP. In human Treg cells, a positive feedback
loop has been found between GARP and FOXP3; this feedback loop is interrelated with the FOXP3-enhancing molecules indicated.
Phosphorylation of LGALS3 (indicated by a P) has been reported to be essential for the FOXP3-regulating function [21]. GARP is a receptor for
LAP/latent TGF-b [26,27]. T-bet (T-box expressed in T cells), GATA3 (GATA-binding protein 3), RORg (retinoic-related orphan receptor gamma)
represent transcription factors of Th1, Th2, and Th17 cells. (B) Implications for human and murine T cells, respectively, of the autocrine and
paracrine effects of GARP and Nrp1 surface-bound LAP/latent TGF-b after activation of TGF-b. The TGF-b signature phospho-SMAD2 (pSMAD2)
has been observed in human (GARP
+) and murine (Nrp1
+)T reg cells. Paracrine effects include the generation of infectious tolerance. (C)
Structural composition of the LAP/latent TGF-b binding proteins Nrp1 and GARP (LRR, leucine-rich repeat domain; CUB, complement
subcomponents C1r/C1s domain; F5/8 coagulation factor domain; MAM, meprin, A5, and receptor protein-tyrosin phosphatase μ domain; TM,
transmembrane region; L, leader peptide). NIP (Nrp1 interacting protein) is a Nrp1 binding protein involved in the regulation of Nrp1-mediated
signaling as a molecular adapter [48].
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of GARP in murine Treg cells?
The identification of GARP as a receptor for LAP/latent
TGF-b opens speculation about a potential common
denominator. The reason for such speculation is that
neuropilin 1 (Nrp1), which has been characterized as a
marker of CD4
+CD25
+ Treg cells in mice that enhances
Treg cell/dendritic cell contact during antigen recogni-
tion [42,43], has also been characterized as a receptor
for LAP/latent TGF-b [39]. Moreover, murine sorted
Nrp1
- T cells capture soluble Nrp1 (applied as a con-
stant fragment [Fc]-fusion protein), and the captured
Nrp1 increases their ability to bind LAP/TGF-b1. Such
coated T cells acquire strong regulatory activity [39].
Thus, Nrp1 is a TGF-b1 receptor that, unlike GARP
[27], also activates the latent form of TGF-b1.
The structural differences between GARP, a Toll-like
receptor homologue with leucine-rich repeats, and the
multi-domain protein Nrp1, a receptor for class-3 sema-
phorin-family proteins and vascular endothelial growth
factor (Figure 1c) [44], necessitate further biochemical
and molecular analyses to identify specific binding inter-
actions and potentially associated molecules. The issue
of GARP expression in murine Treg cells at the protein
level remains to be elucidated.
Discussions
Open Questions Concerning the Function of GARP
Because GARP is constitutively expressed on platelets
[26,45], and because a potential function of GARP on
thrombus formation has recently been reported [46],
important questions about GARP signaling and parallel
function in platelets compared to Treg cells could be
considered. Concerning the dependence of GARP
expression on FOXP3 as described above, it has been
reported that FOXP3 is expressed by human and murine
megakaryocytes [47]. Therefore, the thrombocytopenia
and platelet abnormalities experienced by some patients
with IPEX syndrome can be explained by loss of func-
tion of FOXP3 [47]; however, this explanation would
suggest a concomitant impairment of GARP expression
and function on IPEX platelets, an impairment that has
not yet been shown.
A controversial issue is the potential suppressor func-
tion of GARP, suggested recently [24], because platelets
as a natural source of GARP-expressing cells do not
function as suppressor cells [21]. Therefore, differences
in the function of GARP in platelets and Treg cells can be
suggested. This question is important for the potential
design of GARP-selective drugs that can specifically tar-
get only Treg cells and not platelet functions. As of now,
neither the ligand nor the signaling system or potential
co-receptor(s) of GARP has been identified, and identify-
ing them is the most important challenge for the future.
Conclusions
The identification of GARP as a lineage-specific key
receptor of human activated Treg cells, which is in part
controlled by lineage-specific hypomethylation of the
GARP locus, the characterization of a GARP-FOXP3
positive feedback loop that safeguards FOXP3 expres-
sion in Treg cells, and the binding of LAP/latent TGF-b
to GARP provide a conceptual framework for a new
molecular definition of the regulatory program. If GARP
is a receptor for the well-known immune modulator
TGF-b on human Treg cells, and if Nrp1 plays this same
role on murine Treg cells, then this similarity might
explain the similarities in the TGF-b signatures that
have been observed in Treg cells in both species. The
surface binding and activation of TGF-b have obvious
implications for infectious tolerance. Complete elucida-
tion of the GARP/GARP-ligand signaling system in Treg
cells and platelets is an important challenge and a prere-
quisite for the future development of strategies and tools
for inducing or inhibiting Treg cells in chronic infection,
tumor immunotherapy, autoimmune diseases, and
transplantation.
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immune dysregulation, polyendocrinopathy, enteropathy,
X-linked; iTreg cells: induced regulatory T cells; LAP:
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Reviewer 1: Dr. Jim Di Santo, Cytokines and Lymphoid
Development Lab, Institut Pasteur, Paris, France
Reviewer’s comment: I have read your comment for
Biology Direct entitled “FOXP3 and GARP (LRRC32):
the master and its minion”.If i n dt h i sc o m m e n tt ob e
interesting and suitable for publication in Biology Direct.
I do not have any specific comments for web
publication.
Reviewer’s report 2
Reviewer 2: Dr. Benedita Rocha, Institut National de la
Santé et de la Recherche Médicale (INSERM) U591, Insi-
tut Necker, France
Reviewer’sc o m m e n t :R e g u l a t o r yc e l l sh a v eaf u n d a -
mental role in many disease processes, and extensive
experimental and clinical data indicate that tools pre-
venting or increasing regulatory function will have a
fundamental therapeutic role. While FOXP3 expression
generally correlates with regulation in the mouse, this is
not so in human T cells. This comment reviews a
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Page 4 of 6fundamental aspect, the factors besides FOXP3 expres-
sion that ensure the induction of a stable regulatory
function on human cells, their correlation with FOXP3
regulation and their possible mechanisms of action. I
found the topic actual and important, the comment
clear and comprehensive and strongly support
publication.
Reviewer’s report 3
Reviewer 3: Dr. Werner Solbach, Insitute for Medical
Microbiology and Hygiene, University Lübeck, Germany
Reviewer’s comment: The ms. deals with the connec-
tivity of FOXP3 and “glycoprotein - A repititions predo-
minant receptor (GARP or LRRC32) in the context of
the functioning of regulatory T cells (Tregs). This topic
is of great relevance in the context of clarifying the
equivocal role of FOXP3 and its partners for explanation
of regulatory T cell circuits. It is clear that not only
FOXP3 or GARP alone, but also latently activated TGF-
b is crucial for the suppressive activity of Treg cells.
The authors now very nicely bring together the GARP -
FOXP3 regulatory circuit with the autocrine TGF-b
loop which helps to explain many Treg features. In their
perspective, they also try to open thoughtful avenues
how to bring together (human) GARP with its possible
functional homologue in mice, neuropilin 1. In sum-
mary, they present a valuable conceptual framework for
understanding the regulatory program in the T cell reac-
tivity system and beyond. The ms. is well written and
easy to understand. I recommend publication in Biology
Direct.
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